Editorial
Radioembolization in the setting of liver transplantation: great expectations or hard times?
Abstract
Trans-arterial radio-embolization (TARE) with yttrium-90 represents one of the most efficacious approaches for the treatment of selected patients with advanced hepatocellular cancer (HCC) (1). Recent studies have confirmed the superiority of TARE when compared with other intraarterial treatments (2,3).